HEMO Share Price Performance
UK£9.26
5.87 (172.75%)
88.4% undervalued intrinsic discount
UK£80.00
Fair Value
Price UK£9.26
FactsNotFiction UK£80.00
Fair ValueUK£80.00
Share Pricen/a
Hemogenyx Pharmaceuticals Plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
HEMO Community Narratives
FA
Fair Value UK£80 88.4% undervalued intrinsic discount
Significantly undervalued due to several years of reliance on poor UK funding options moving to US based investment.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Significantly undervalued due to several years of reliance on poor UK funding options moving to US based investment.
Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.Read more
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
FA
UK£80
88.4% undervalued intrinsic discount
FactsNotFiction's Fair Value
Profit Margin
19.78%
Future PE
27.05x
Price in 2029
UK£0
Trending Discussion
Recently Updated Narratives
FA
Significantly undervalued due to several years of reliance on poor UK funding options moving to US based investment.
Fair Value: UK£80 88.4% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Hemogenyx Pharmaceuticals Plc Key Details
About HEMO
- Founded
- 2013
- Employees
- 16
- CEO
- WebsiteView website
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
